Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25271583 | 1.00 | HTR2C (0.51) | HTR2CESR2PDE4APDE4BPDE4C | |
| SCHEMBL25227729 | 1.00 | HTR2C (0.51) | HTR2CESR2PDE4APDE4BPDE4C | |
| SCHEMBL430771 | 0.90 | HTR2C (0.49) | HTR2CESR2PDE4APDE4BPDE4C | |
| SCHEMBL430772 | 0.90 | HTR2C (0.49) | HTR2CESR2PDE4APDE4BPDE4C | |
| SCHEMBL6891029 | 0.89 | HTR2C (0.59) | HTR2CESR2DDB1CRBNCYP1A2 | |
| SCHEMBL27956890 | 0.86 | ESR2 (0.38) | HTR2CESR2PDE4APDE4BPDE4C | |
| SCHEMBL427824 | 0.85 | HTR2C (0.53) | HTR2CKDM1AMAOB | |
| SCHEMBL10699304 | 0.82 | ESR2 (0.46) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5329450 | 0.81 | MAPT (0.57) | HTR2CKDM1AMAOB | |
| SCHEMBL717834 | 0.79 | ESR2 (0.50) | ESR2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398781-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | CONVELO THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4436975-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118696050-A | Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023097233-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097233-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398781-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, PMP22, NR1H2 | HTR2C 4574/4885ESR2 1747/4885PDE4A 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.